Datar Cancer Genetics discovered the first-of-its-kind TriNetra™-Glio, a blood test to diagnose brain tumours.
TriNetra™ Glio-Liquid Biopsy is designed to detect cells released from the blood of a brain tumour which is extremely rare.
TriNetra™-Glio, a blood test is considered to be highly sensitive and specific. This new technology consisting of true diagnostic utility will detect cells rather than picking up molecular indicators of disease, which until now has depended on liquid biopsies.
A test requires 15 ml of blood sample and is intended for patients where a brain biopsy cannot be performed even if it is necessary or unsuccessful.
This test can change clinical practice and significantly help patients with hard-to-reach brain tumours.
Brain cancer is the 10th leading cause of cancer in India, causing more than 26,000 adult deaths every year. Diagnosing brain tumours is resourceful, and risky, and in almost 40 per cent of advanced cases, it is impossible to perform. Currently, there are no blood tests available to diagnose brain cancer in the world, and doctors must use complex surgical procedures to acquire tumour tissue for histopathological evaluation.
US Food and Drug Administration (FDA) grants breakthrough device designation for 'TriNetra™-Glio', a blood test to help diagnose brain tumours.
